Back to Screener

Healthcare

Carna Biosciences, Inc.(CBIXF)

Live Price

Offline

$10.75

+0.00% today

1Y Change

Window

No data

Market Cap
Revenue Growth
0.0%
EPS Growth
0.0%
Dividend Yield
0.0%
No coverage

Historical coverage is still loading

We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.

No price data

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Carna Biosciences, Inc. (CBIXF) is a Healthcare stock. The stock last traded around $10.75. Baseline metrics include revenue growth of 0.0%, EPS growth of 0.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS 0.0%, free cash flow 0.0% with operating margin -358.3% and ROIC -192.4%. Valuation already assumes a fairly strong business story at price/sales 12.9. Stock Foundry combines CBIXF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Sector Context

How this name stacks up against nearby peers on first-pass metrics.

Revenue Growth

Below sector median

0.0% vs +7.6% peer median

Operating Margin

Below sector median

-358.3% vs +19.4% peer median

What Changed This Quarter

Latest report context and the signals most likely to have changed the story.

Latest report is on the board

2022 was reported on Nov 7, 2022, but the surprise data is still limited.

The setup is mixed rather than one-directional

Revenue is 0.0% and EPS is 0.0%, while operating margin sits near -358.3%.

Benchmark Edge

CBIXF vs SPY, QQQ, and Sector ETFs

Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.

Shared 1Y chart + MAX history table

CBIXF

Normalized return

SPY

--

S&P 500

Excess Return

--

Relative to SPY

CBIXF Max Drawdown

Trailing 1Y

SPY Max Drawdown

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for CBIXF and SPY.

Calendar-year return history is still loading or unavailable.
CA

Company Overview

Carna Biosciences, Inc.

Last Updated
May 7, 2026

Key Fundamentals

Valuation, growth, profitability, and balance sheet signals.

Valuation

P/E
EV/EBITDA
Price/Sales
12.9
Price/Book
24.0

Growth

Revenue
0.0%
EPS
0.0%
Free Cash Flow
0.0%

Profitability

Gross Margin
67.0%
Operating Margin
-358.3%
Net Margin
-375.0%
ROE
-192.1%
ROIC
-192.4%

Balance Sheet

Debt/Equity
2.31
Current Ratio
6.99

Earnings Reports

📅 Last reportedNov 7, 2022
PeriodB/MEPSEPS ΔRevenueRev Δ
Nov 7, 22
-31.92
Est
Est
Aug 5, 22
-25.25
Est
Est
May 10, 22
-1.12
Est
Est
Feb 10, 22
48.47
Est
Est
Nov 8, 21
-31.67
Est
Est
Aug 6, 21
-39.46
Est
Est
May 10, 21
-23.09
Est
Est
Feb 12, 21
-37.24
Est
Est
Nov 9, 20
-20.29
Est
Est
Aug 7, 20
-17.35
Est
Est
May 12, 20
-15.25
Est
Est
Feb 7, 20
-24.75
Est
Est
Nov 8, 19
-9.70
Est
Est
Aug 13, 19
137.02
Est
Est
May 13, 19
Est
Est
Feb 8, 19
-38.90
Est
Est

Latest News

No news articles available

Official Releases

Company announcements and filings-style updates.

Official
No official releases available

Next Step

Keep the research moving

After the overview, the strongest next step is usually chart context or a tighter compare set.